While we gather around the table on Thursday, many of us will give thanks for the blessings in our lives. Will workers’ comp be among them? In this edition of Inside Workers’ Comp, we asked industry experts Chikita Mann, Mark
More stories
Workers' Comp
Blog
Topical Treatments - Their Impact on Drug Spend and Utilization
Topicals place fourth in overall cost among the 10 most expensive drug classes in workers’ comp. These include prescription nonsteroidal anti-inflammatory drugs (NSAIDs) and other formulations, such as creams and patches designed to treat pain.
Workers' Comp
Article
StateWatch: Bill Review May 2018
Keep current with new legislation and its potential effect on your organization. This regulatory update is for informational purposes only, and provides some key highlights on state initiatives that may impact the bill review services Genex provides.
Mitchell
News Release
Hawaii Legislature Sends Opioid Limits Bill to Governor
Hawaii legislature sends new opioid legislation to Governor for approval.
Mitchell
Article
Insurtech: Improving Consumer Experiences and Relationships
Technology is one of the hottest topics in insurance, as Insurtech innovations continue to disrupt the industry. Between improving customer experiences and relationships, helping contain costs and using data to improve decision-making, technology has been and will continue to make significant improvements in Property & Casualty claims handling.
Mitchell
News Release
Oklahoma Joins Growing Chorus of States Limiting Opioids
New opioid-limiting legislation has been signed into law in Oklahoma.
Workers' Comp
Article
Quarterly Drug Update: Pharmacy Drug Spend
CompPharma's 2018 Annual Survey of Prescription Drug Management in Workers' Comp found that, in the past eight years, drug spend has decreased 31.5% among those surveyed in workers’ compensation. Part of this is due to increased focus on dangerous opioid prescribing behaviors and the implementation of state-mandated formularies. Opioid spend has decreased for the same group by around 18.22% in the past year and payers and PBM’s have been able to reduce opioid spend by about one third in the last two years.